Oragenics Inc. (NYSE American: OGEN) announced active enrollment at a second site in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury, with four patients already dosed at its initial Australian site. The company is progressing toward a planned data readout by year-end 2026, according to a press release.
The advancement marks a significant step for the clinical-stage biotechnology company, which is developing brain-targeted therapeutics through proprietary intranasal delivery technology. Oragenics is working on advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow.
Concussion and mild traumatic brain injury represent a significant unmet medical need, affecting millions of individuals annually. Current treatment options are limited, often focusing on symptom management rather than addressing the underlying pathophysiology. ONP-002 is designed to target the brain directly via intranasal delivery, potentially offering a novel therapeutic approach.
Oragenics’ intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. The company is committed to developing innovative therapies that address significant unmet needs in neurological care.
The Phase IIa trial is evaluating the safety, tolerability, and efficacy of ONP-002 in patients with concussion. The expansion to a second site is expected to accelerate enrollment and provide additional data to support the development program. The company anticipates a data readout by year-end 2026, which will be critical for determining the next steps in clinical development.
For more information about Oragenics and its pipeline, visit oragenics.com. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.
